Citius Oncology, Inc. Notes Payable, Current
Citius Oncology, Inc. (CTOR) had Notes Payable, Current of $1.72 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2024-08-09
- 2024-06-30: Notes Payable, Current $1.72M.
- 2024-03-31: Notes Payable, Current $1.52M.
- 2023-12-31: Notes Payable, Current $1.32M.
| Period end | Notes Payable, Current |
|---|---|
| 2024-06-30 | $1.72M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $1.52M 10-Q · filed 2024-05-20 |
| 2023-12-31 | $1.32M 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |